Crossmark

Perceived barriers and opportunities to the continuous distribution of ivermectin in the Cameroon primary health care system: an exploratory study of major stakeholders

Crossref DOI link: https://doi.org/10.1186/s12913-026-14863-x

Published Online: 2026-06-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wafeu, Guy Sadeu

Makoge, Valerie

Simo, Loirette Simo

Nana-Djeunga, Hugues Clotaire

Kamgno, Joseph
License Information

Text and Data Mining valid from 2026-06-04

Accepted Manuscript valid from 2026-06-04
More Information

Article History

Received: 8 November 2024

Accepted: 27 May 2026

First Online: 4 June 2026

Declarations

:

: The study began only after obtaining all necessary approvals, including administrative research authorization and ethical clearance Number CBI/477/ERCC/CAMBIN from Cameroon Bioethics Initiative (CAMBIN). The research process aligned with the principles and protocols outlined in the current Declaration of Helsinki. We briefed participants on the study’s purpose and obtained their consent before proceeding.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below